If you have been reading about animal model and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-11-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | Linear, fifteen residues |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Approximate mass | 1419 Da | Value reported for the free peptide |
| Reported origin | Fragment of a gastric juice protein | Used as the design template |
| Common synonyms | Body protection compound 157; PL 14736 | Naming varies across papers and suppliers |
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
As of 2014, it has 450 employees working at 3 locations, including distribution centers in North Las Vegas, NV; Shiremanstown, PA; and Bedfordshire, U.K. The corporate headquarters is also located in Boise, along with the company's customer service call center. In 2013, the company donated the equipment for Boise's first outdoor gym, located in Ann Morrison Park. In September 2015, Ryan Deluca suddenly announced he would be stepping down from his position as CEO. In November, Liberty Interactive spun off Bodybuilding.com and its stake in Expedia into a new company, Liberty Expedia Holdings. After Bodybuilding.com laid off 90 people in December 2016, it reorganized to form 4 different companies/brands. In February 2019, hackers accessed some part of Bodybuilding.com's corporate IT systems, and may have retrieved personal data of the site's users. Sometime in the next few months, the company discovered this, but did not publicize it right away, instead hiring a security company to assess what their vulnerability had been. It was found that at least one of Bodybuilding.com's 450 employees had been susceptible to a phishing email sent in July 2018. It was not determined if the hackers accessed user data. In April 2019, Bodybuilding.com publicized the breach, saying its consequences were unknown, and reset all the passwords of the site's users.
=== Visual Effects === The Lord of the Rings: The Fellowship of the Ring (2001) (lead massive crowd technical director) The Lord of the Rings: The Two Towers (2002) (senior massive technical director) The Matrix Reloaded (2003) (lead technical director) The Matrix Revolutions (2003) (sentinel/swarm lead) The Lord of the Rings: The Return of the King (2003) (senior massive technical director) Catwoman (2004) (CG supervisor) Drawing Restraint 9 (2005) (lead technical director) Pirates of the Caribbean: Dead Man's Chest (2006) (digital artist)
Diagnosis of ILD involves assessing the signs and symptoms as well as a detailed history investigating occupational exposures. ILD usually presents with dyspnea, worsening exercise tolerance and 30-50% of those with ILD have a chronic cough. On examination, velcro crackles, in which the crackles compare to the sound of velcro being unfastened, are common in ILD. Pulmonary function tests usually show a restrictive defect with decreased diffusion capacity of carbon monoxide (DLCO) indicating reduced alveolar to blood capillary transport. Pulmonary function testing is indicated for all people with ILD and the FVC loss and DLCO is prognostic, with an FVC loss of greater than 5% per year associated with a poor prognosis in fibrosis subtypes of ILD. A chest x-ray is 63% sensitive and 93% specific for ILD. With advances in computed tomography, CT scans of the chest have supplanted lung biopsy as the preferred diagnostic test for ILD. A thoracic CT scan is 91% sensitive and 71% specific for ILD. In higher income countries, less than 10% of people with ILD undergo a lung biopsy as part of the diagnostic evaluation. A lung biopsy may be required if the clinical history and imaging are not clearly suggestive of a specific diagnosis or malignancy cannot otherwise be ruled out. Surgical lung biopsy or via a video-assisted thoracoscopic surgery (VATS) biopsy is associated with a mortality rate up to 1-2%.
Sources: en.wikipedia.org
A recent technique for structure elucidation in mass spectrometry, called precursor ion fingerprinting, identifies individual pieces of structural information by conducting a search of the tandem spectra of the molecule under investigation against a library of the product-ion spectra of structurally characterized precursor ions. Particularly unstable ions may disintegrate while passing through the analyzer. If it undergoes the reaction Mz+ → M'z+ + (other parts) when entering the analyzer, it would undergo a circular motion of radius
The Ottomans, through the Ma'n dynasty, a great Druze feudal family, and the Shihabs, a mixed Sunni Muslim-Druze family that had converted to Christianity. Ma'n dynasty were a family of Druze chiefs of Arab stock based in the rugged Chouf area of southern Mount Lebanon who were politically prominent in the 15th–17th centuries. Deir al-Qamar was the capital and the residence of the Emirate of Mount Lebanon. The Church of Saidet et Tallé is a Maronite church in Deir el Qamar in Lebanon, it is one of the most important historical and religious sites in Deir el Qamar and dates to the 16th century. The second church was destroyed by the Saracens and rebuilt during Fakhreddine 1st Maan's (1518–1544) reign. In 1673, Sheikh Abu Fares Karam of Ehden (Emir Ahmad Ma'n's secretary) and his brother Sheikh Abu Nader enlarged the church and added a vault. During the reign of Bechir II Chehab (1789–1840) it was again enlarged and renovated. Fakhr-al-Din II (1572–1635) was a Druze prince and a leader of the Mount Lebanon Emirate. For uniting modern Lebanon's constituent parts and communities, especially the Druze and the Maronites, under a single authority for the first time in history, he is generally regarded as the country's founder. Christians prospered and played key roles under his rule, with his main enduring legacy being the symbiotic relationship he set in motion between Maronites and Druze, which proved foundational for the creation of a Lebanese entity. Maronite Abū Nādir al-Khāzin was one of his foremost supporters and served as Fakhr-al-Din's adjutant.
== Skin care properties == Aleppo soap can be used daily as soap for washing and shampooing, as face mask, as shaving cream, and for bathing infants and babies. Laurel oil is an effective cleanser, with some antimicrobial, antifungal and anti-itching properties.
Sources: en.wikipedia.org
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.
The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.
No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.